2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i [j] k l m n o p q r s t u v w x y z

Abstract Number: 1280

JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Abstract Number: 2468

JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis
Abstract Number: 1859

Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Abstract Number: 1338

Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Abstract Number: PP09

Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius
Abstract Number: 2713

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Abstract Number: 1709

Juvenile-Onset IgG4-Related Disease: A Systematic Review

Jump to: View All • a b c d e f g h i [j] k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].